Kalaris Therapeutics (KLRS) Other Operating Expenses (2023 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Other Operating Expenses of -$15.5 million for Q1 2026, down 59.52% year-over-year from -$38.3 million in Q1 2025, and up 57.61% quarter-over-quarter from -$36.6 million in Q4 2025.
Kalaris Therapeutics (KLRS) Other Operating Expenses (2023 - 2026) Analysis & Trends
Kalaris Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at -$15.5 million for Q1 2026.
- In Q1 2026, Other Operating Expenses fell 59.52% year-over-year to -$15.5 million; the TTM figure through Mar 2026 stood at -$53.9 million (down 14.61% YoY), while the FY2025 annual figure was -$61.3 million, down 2035.58% from the prior year.
- Other Operating Expenses for Q1 2026 stood at -$15.5 million, up from -$36.6 million in the prior quarter.
- The five-year high for Other Operating Expenses was $18.6 million in Q4 2023, with the low at -$36.6 million in Q4 2025.
- The 4-year median for Other Operating Expenses is -$4.2 million (2024), against an average of -$8.3 million.
- Peak annual rise in Other Operating Expenses reached 1387.29% in 2025, while the deepest fall reached 3804.02% in 2025.
- Kalaris Therapeutics' Other Operating Expenses stood at $18.6 million in 2023, then sank by 291.86% to -$35.6 million in 2024, then fell by 2.67% to -$36.6 million in 2025, then surged by 57.61% to -$15.5 million in 2026.
- Business Quant data shows KLRS's Other Operating Expenses at -$15.5 million in Q1 2026, -$36.6 million in Q4 2025, and -$7.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.15 Mn |
| Mar 31, 2026 | -15.51 Mn |
| Dec 31, 2025 | -36.58 Mn |
| Sep 30, 2025 | -7.17 Mn |
| Jun 30, 2025 | 5.37 Mn |
| Mar 31, 2025 | -9.72 Mn |
| Dec 31, 2024 | -35.63 Mn |
| Sep 30, 2024 | -1.25 Mn |
| Jun 30, 2024 | -417,000.00 |
| Mar 31, 2024 | -249,000.00 |
| Dec 31, 2023 | 18.57 Mn |